Effects of Proton Pump Inhibitor Coadministration on the Plasma Concentration of Erlotinib in Patients With Non–Small Cell Lung Cancer
Authors:
- 1 December 2018
- journal article
- research article
- Published by Wolters Kluwer Health in Therapeutic Drug Monitoring
- Vol. 40 (6) , 699-704
Abstract
Background: Erlotinib is used for treating non–small cell lung cancer (NSCLC). Intestinal absorption of erlotinib is impaired under gastric pH elevation; therefore, coadministration of gastric acid suppressants may provide lower blood concentration of erlotinib. We investigated the effects of erlotinib coadministration with proton pump inhibitors (PPIs) and histamine H2receptor blockers (H2RBs) on the plasma concentration of erlotinib and erlotinib-induced adverse reaction in patients with NSCLC.Methods: Forty-two patients receiving erlotinib therapy for NSCLC were recruited for this study. Association of adverse reactions (rash and diarrhea) with plasma concentration of erlotinib was examined. Plasma concentration-to-dose (C/D) ratios and oral clearance (CL/F), which was estimated by population pharmacokinetic analysis of plasma concentrations of erlotinib, were compared among 3 patient groups: without coadministration of gastric acid suppressants (control group), with coadministration of PPI (PPI group), and coadministration of H2RB (H2RB group).Results: Patients with grade ≥2 rash had higher plasma concentrations of erlotinib compared with those with grade ≤1 [1.02 (0.43–2.60) versus 0.67 (0.10–1.85) mcg/mL,P< 0.01]. The C/D ratios of erlotinib in the PPI and H2RB groups were lower than that in the control group [0.39 (0.08–0.76) and 0.48 (0.33–0.81) versus 0.51 (0.28–1.28) mcg·mL−1·mg−1·kg−1], where statistical significance was observed between PPI and control groups (P< 0.05). The population pharmacokinetic estimated oral CL/F in the PPI and H2RB groups were higher than that in the control group [5.55 (3.36–14.52) and 4.82 (2.08–6.32) versus 3.95 (2.01–10.44) L/h], where statistical significance was observed between PPI and control groups (P< 0.05).Conclusions: Plasma concentrations of erlotinib in patients under coadministration of gastric acid suppressants were lower than those without gastric acid suppressants through drug interaction, suppressing the intestinal absorption of erlotinib. The magnitude of this drug interaction was more pronounced in the coadministration of PPI compared with H2RB.Keywords
This publication has 17 references indexed in Scilit:
- A Simple High-Performance Liquid Chromatography for Determining Lapatinib and Erlotinib in Human PlasmaTherapeutic Drug Monitoring, 2016
- EGFR kinase inhibitors and gastric acid suppressants in EGFR-mutant NSCLC: a retrospective database analysis of potential drug interactionOncotarget, 2016
- Association of concurrent acid-suppression therapy with survival outcomes and adverse event incidence in oncology patients receiving erlotinibCancer Chemotherapy and Pharmacology, 2016
- Effect of gastric pH on erlotinib pharmacokinetics in healthy individualsAnti-Cancer Drugs, 2015
- Gastric Acid Suppression Is Associated With Decreased Erlotinib Efficacy in Non–Small-Cell Lung CancerClinical Lung Cancer, 2015
- An evaluation of the possible interaction of gastric acid suppressing medication and the EGFR tyrosine kinase inhibitor erlotinibLung Cancer, 2013
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialThe Lancet Oncology, 2012
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 studyThe Lancet Oncology, 2011
- Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials GroupJournal of Clinical Oncology, 2007
- Erlotinib in Previously Treated Non–Small-Cell Lung CancerNew England Journal of Medicine, 2005